scholarly journals Incidence of Epilepsy among elderly Sudanese patients with Alzheimer’s disease: A prospective cohort study on 480 patients, Khartoum, Sudan, 2019

2021 ◽  
Author(s):  
Abbasher Hussien Mohamed Ahmed ◽  
Khabab Abbasher Hussien Mohamed Ahmed ◽  
Mohammed Eltahier Abdalla Omer ◽  
Amira Siddig
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Late Onset ◽  
Brain Mri ◽  
Cerebral Atrophy ◽  
Incidence Rates ◽  
Increased Risk

Abstract Background: An increased prevalence of epilepsy had been documented with dementia. Alzheimer’s disease and epilepsy often coexist. Objective: The aim of this study to assess incidence rates of epilepsy among Sudanese patients with Alzheimer’s disease. Methods: This is a prospective cohort study. We followed 480 patients aged more than 65 years with diagnosis of Alzheimer’s disease between May 2006 and May 2019 looking for coexist epilepsy. Results: Regarding Alzheimer’s disease female were affected more than male (60%). 10% of our patients have epilepsy. Generalize epilepsy was the most common type (62%). Epilepsy was more common with late onset Alzheimer’s disease. Abnormal EEG was detected in 20% of our studied group. Abnormal Brain MRI in form of cerebral atrophy was observed in 60 % of patients with Alzheimer’s disease and epilepsy. Conclusion: Patients with Alzheimer’s disease have an increased risk of developing epilepsy. There is strong relation between disease duration and development of epilepsy.

scholarly journals Dual-task as a predictor of falls in older people with mild cognitive impairment and mild Alzheimer's disease: a prospective cohort study

2018 ◽  
Vol 22 (5) ◽  
pp. 417-423 ◽  
Author(s):  
Jessica Gonçalves ◽  
Juliana Hotta Ansai ◽  
Fernando Arturo Arriagada Masse ◽  
Francisco Assis Carvalho Vale ◽  
Anielle Cristhine de Medeiros Takahashi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cohort Study ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Older People ◽  
Prospective Cohort Study ◽  
Dual Task ◽  
Prospective Cohort

Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer’s Disease in a Prospective Cohort Study

2020 ◽  
Vol 75 (2) ◽  
pp. 417-427
Author(s):  
Yi-Fang Chuang ◽  
Vijay Varma ◽  
Yang An ◽  
Toshiko Tanaka ◽  
Christos Davatzikos ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cohort Study ◽  
Apolipoprotein E ◽  
Prospective Cohort Study ◽  
Prospective Cohort

scholarly journals Association of postoperative covert stroke and cognitive dysfunction among elderly patients undergoing non-cardiac surgery: protocol for a prospective cohort study (PRECISION study)

BMJ Open ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. e034657 ◽  
Author(s):  
Qianyu Cui ◽  
Dexiang Wang ◽  
Min Zeng ◽  
Jia Dong ◽  
Hailong Jin ◽  
...  
Keyword(s):  
Cardiac Surgery ◽  
Cohort Study ◽  
Elderly Patients ◽  
Cognitive Dysfunction ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Brain Mri ◽  
Postoperative Cognitive Dysfunction ◽  
Ageing Population ◽  
Increased Risk

IntroductionThe incidence of covert stroke and cognitive dysfunction has gradually increased due to an ageing population. Recently, a prospective cohort study reported perioperative covert stroke was associated with an increased risk of postoperative cognitive dysfunction (POCD) 1 year after non-cardiac surgery. However, the mechanism remains unclear.Methods and analysisThis is a prospective observational trial aiming to investigate the cumulative incidence of perioperative covert stroke and test the hypothesis that perioperative covert stroke associates with POCD in elderly patients undergoing non-cardiac and non-neurological surgery. Data on risk factors, brain MRI, cognitive function evaluation and serum immune-inflammatory cytokines will be collected and analysed.Ethics and disseminationEthical approval has been granted by the Medical Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (reference number: KY2017-027-02). The results of this study will be disseminated through presentations at scientific conferences and publication in scientific journals.Trial registration numberNCT03081429.

scholarly journals DL-3-n-butylphthalide Delays Cognitive Decline in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil: A Multicenter, Prospective Cohort Study

2020 ◽  
Author(s):  
Jin Wang ◽  
Xiaojuan Guo ◽  
Wenhui Lu ◽  
Jie Liu ◽  
Hong Zhang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Logistic Regression ◽  
Regression Analysis ◽  
Cohort Study ◽  
Activities Of Daily Living ◽  
Cognitive Decline ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Daily Living

Abstract Background：Vascular factors and mitochondria dysfunction contributeto thepathogenesis of Alzheimer’s Disease (AD).DL-3-n-butylphthalide (NBP)has an effect in protecting mitochondria and improving microcirculation. We investigated the effect of NBP in patients with mild-moderate AD already receiving donepezil.Methods: It was a prospective cohort study. 92 mild-moderate AD patients were classified into the donepezil alone group (n=43) or the donepezil combined NBP group (n=49) for 48 weeks. The primary outcome was change of Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog) from baseline after treatment 48 weeks. All patients were also evaluated with clinician’s interview-based impression of change plus caregiver input (CIBIC-plus), Alzheimer's disease cooperative study-activities of daily living (ADCS-ADL) and neuropsychiatric inventory (NPI) every 12 weeks. All patients were monitored for adverse events (AEs). The efficacy was analyzed using logistic regression analysis.Results:The univariate analysis showed that age wasolder in donepezil alone group(P=0.005), prevalence of hypertension was higher in donepezil alone group(P=0.026).The ADAS-cog score change from baseline in thedonepezil alone group was significant than that in the donepezil combined NBP group at 48 weeks(1.82±5.20 vs -0.38±4.46, P=0.048). The multivariate logistic regression analysis showed that between the 2 groups, there were significant differencesin changes on the ADAS-cog(OR=0.879,95% CI:[0.785,0.984],P=0.026),MMSE(OR=1.270,95% CI:[1.036,1.557],P=0.021), and ADCS-ADL(OR=1.067,95% CI:[1.002,1.136],P=0.042) but no significant differences for changes on the NPI(OR=0.955,95% CI:[0.901，1.013],P=0.125)and CIBIC-plus (OR=0.356,95% CI:[0.093,1.364],P=0.132). The occurrence of AEs was similar in the 2 groups.Conclusions:Over the 48-week treatment period, donepezil combined NBP group had slower cognitive decline and better activities of daily living in patients with mild to moderate AD. These indicated that the multi-target therapeutic effect of NBP may be a new choice for AD treatment.Trial registration:Clinical trial registration URL:https://clinicaltrials.gov/ct2/show/NCT02711683?term=NCT02711683&draw=2&rank=1ClinicalTrials.gov Identifier: NCT02711683. Date of registration: March 14,2016.

P1-258: Post-menopausal hormone therapy and Alzheimer's disease: A prospective cohort study

2015 ◽  
Vol 11 (7S_Part_9) ◽  
pp. P452-P453
Author(s):  
Bushra Imtiaz ◽  
Anna-Maija Tolppanen ◽  
Hilkka Soininen ◽  
Miia Kivipelto ◽  
Marjo Tuppurainen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cohort Study ◽  
Hormone Therapy ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Menopausal Hormone Therapy ◽  
Post Menopausal
Sign in / Sign up

Export Citation Format

Share Document